尤瑞克林联合巴曲酶治疗急性脑梗死的疗效观察

The efficacy of urinary kallidinogenase plus batroxobin in the treatment of acute cerebral infarction

目的 观察尤瑞克林联合巴曲酶治疗急性脑梗死的疗效.方法 收集急性脑梗死患者105例,将患者按治疗方法不同分成三组,尤瑞克林组35例,尤瑞克林和巴曲酶合用组（联合组）39例,巴曲酶组31例.三组在治疗前和治疗10 d后,作NIHSS评分、巴氏量表评分、MRS评分,比较临床疗效.结果 三组NIHSS评分治疗后较治疗前均下降（均P＜0.05）,联合组显著有效率为79.5％（31/39）,优于尤瑞克林组的71.4％ （25/35）和巴曲酶组的35.4％ （11/31）（χ^2=15.801,P=0.001）,但改良Rankin量表（MRS）评分和日常生活活动能力量表（巴氏量表）评分仅优于巴曲酶组（P =0.003）,并不优于尤瑞克林组（P=0.766）.结论 尤瑞克林联合巴曲酶治疗急性脑梗死有效,其近期疗效均优于单用尤瑞克林和巴曲酶.

Objective To observe the efficacy of urinary kallidinogenase plus batroxobin in the treatment of acute cerebral infarction.Methods 105 patients with acute cerebral infarction were selected and divided into 3 groups：urinary kallidinogenase group （35 cases）,combined treatment group （39 cases）,batroxobin group （31 cases）.The NIHSS score,Barthel Index,MRS score were evaluated before treatment and 10 days after treatment,and the clinical efficacy was compared.Results The NIHSS score significantly decreased after treatment in the three groups （all P 〈 0.05）.The effective rate of combined treatment group was better than that of the single treatment group （urinary kallidinogenase group or batroxobin group） [79.5 % （31/39）,71.4 % （25/35）,35.4% （11/31） （χ^2=15.801,P =0.001）].The Barthel Index and MRS score of combined treatmentgroup were better than those of the batroxobin group （P =0.003）,not better than the urinary kallidinogenase group （P =0.766）.Conclusion Urinary kallidinogenase plus batroxobin is effective in the treatment of acute cerebral infarction.